Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma
(2015). Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
15 May 2015
|
| In: |
Leukemia and lymphoma
Year: 2015, Volume: 56, Issue: 12, Pages: 3320-3328 |
| ISSN: | 1029-2403 |
| Online Access: | Verlag, Volltext: https://www.tandfonline.com/doi/abs/10.3109/10428194.2015.1030641
|
| Author Notes: | Ruben Niesvizky, Ashraf Z. Badros, Luciano J. Costa, Scott A. Ely, Seema B. Singhal, Edward A. Stadtmauer, Nisreen A. Haideri, Abdulraheem Yacoub, Georg Hess, Suzanne Lentzsch, Ivan Spicka, Asher A. Chanan-Khan, Marc S. Raab, Stefano Tarantolo, Ravi Vij, Jeffrey A. Zonder, Xiangao Huang, David Jayabalan, Maurizio Di Liberto, Xin Huang, Yuqiu Jiang, Sindy T. Kim, Sophia Randolph & Selina Chen-Kiang |
| Summary: | (2015). Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. |
|---|---|
| Item Description: | Gesehen am 19.08.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1029-2403 |